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Differential suppression of the tumorigenicity of HeLa and SiHa cells by
adeno-associated virus
P-F Sul2 and F Y-H Wu'
'Division of Cancer Research, Institute ofBiomedical Sciences, Academia Sinica, Taipei 115; 2Graduate Institute ofLife Sciences,
National Defense Medical Center, Taipei 110, Taiwan, Republic of China.
S_nary Adeno-associated virus (AAV) is well known for suppression of oncogenesis in rodents, but its
inhibitory effects on human carcinoma are less well understood. We report the differential ability of AAV to
inhibit the tumorigenicity of two human cervical carcinoma cell lines. The wild-type AAV-2 DNA carried by a
pSV2Neo vector was transfected into HeLa cells, which contain 50 copies of human papillomavirus type 18
(HPV-18), and SiHa cells, which contain 1-2 copies of HPV-16. About 1-3 copies of AAV genome were
introduced per cell. AAV transfection moderately reduced the growth rate and anchorage-independent activity
of the cells. In nude mice, the size of tumours arising from SiHa cells was reduced by 87%, in contrast to no
reduction in tumour size arising from HeLa cells. This suggests that the differential suppression exerted by
AAV may be due to differences in HPV copy number. To define the region that is responsible for the
oncosuppression, mutation analyses were conducted. The results of nude mice assays showed that both the
replication gene and inverted terminal repeats of AAV were important for the inhibition. This study may
provide a model system for further studies on the underlying mechanism of AAV oncosuppressive activity.
Keyword adeno-associated virus; human papillomavirus; human cervical carcinoma cell lines; oncosuppres-
sion; nude mice
The parvoviridae family has been divided into three genera
based on the requirement for helper viruses. Autonomous
parvovirus and densovirus replicate autonomously, whereas
dependovirus needs a helper virus for replication (Siegl et al.,
1985). Autonomous virus and dependovirus interfere with
both spontaneous oncogenesis and experiment-induced
tumours in rodents (Rommelaere and Tattersall, 1990). The
suppression is probably exerted through indirect, e.g. immune
system or direct virus-host interactions (van Pachterbeke et
al., 1993). The underlying mechanism is however still elusive.
Adeno-associated virus (AAV), a dependovirus, signifi-
cantly inhibits carcinogenesis induced by adenovirus (Ad),
herpes simplex virus, bovine papillomavirus (BPV) and the
ras oncogene in rodents (Schlehofer, 1994). In humans, no
known disease has been associated with AAV infection
(Berns and Bohensky, 1987), although recent reports have
shown a linkage ofAAV infection to miscarriage in mice and
humans (Botquin et al., 1994; Tobiasch et al., 1994).
Studies of the effects of AAV on human cancer cells have
led to four main conclusions. (1) AAV infection reduces
human tumour cell proliferation (Bantel-Schaal, 1990),
disturbs the cell cycle (Winocour et al., 1988) and induces
cell differentiation (Bantel-Schaal, 1995; Klein-Bauernschmitt
et al., 1992). (2) Seroepidemiological studies have found that
the incidence of AAV antibody are lower in cervical or
prostate carcinoma patients than in controls (Georg-Fries et
al., 1984; Mayor et al., 1976). (3) AAV infection has been
reported to suppress the promoter activity of human
papillomavirus type 16 (HPV-16) (Hermonat, 1994), while
HPV is one of the potent inducers of cervical carcinoma (zur
Hausen, 1994). (4) AAV infection inhibits in vitro cellular
transformation of rodent cells mediated by BPV, which is a
close relative to HPV (Hermonat, 1989). Taken together, it
seems that AAV infection is reciprocally related to human
cervical carcinoma. However, the inhibitory activity of AAV
in human cells is less well understood than rodents. Nude
mice assay has shown that the tumour growth rate induced
by human cervical carcinoma HeLa cells was moderately
reduced by AAV infection (Walz and Schlehofer, 1992). The
issue of whether AAV can suppress the tumorigenicity of
human cervical carcinoma cells was thus pursued in this
study.
The human AAV type 2 DNA was cloned into a pSV2Neo
vector (Southern and Berg, 1982) to generate a pAVNeo
plasmid. The pSV2Neo or pAVNeo DNA was transfected
into two cervical carcinoma cell lines, HeLa and SiHa. HeLa
contains 10-50 copies of HPV-18 DNA (Schwarz et al.,
1985) per cell and SiHa contains 1-2 copies of HPV-16
DNA (Baker et al., 1987) per cell. The cells were selected by
geneticin and expanded without cloning to avoid possible
misleading conclusions derived from using a particular cloned
cell. A mixed culture is also more similar to the in vivo
condition than a cloned one. To assess whether the
tumorigenicity of carcinoma cells can be affected by AAV
transfection, a nude mouse assay was performed. The in vitro
transformation properties including growth rate and ancho-
rage-independent activity were compared in cells transfected
with or without AAV. The AAV genome consists of a
replication (rep) gene, a capsid (cap) gene (Srivastava et al.,
1983) and two palindromic inverted terminal repeats (ITRs)
(Lusby et al., 1980). To understand the control region for the
oncosuppressive activity, the AAV genome was mutated. The
data indicate that the rep gene and ITRs of AAV but not the
cap gene are important for AAV's inhibitory activity.
Materials and nwthods
Cells
Human cervical carcinoma cell lines, HeLa and SiHa, were
maintained in Dulbecco's modified Eagle medium (DMEM)
and Earle's minimum essential medium (EMEM), respec-
tively. All media were supplemented with 10% heat-
inactivated (56°C, 30 min) fetal calf serum, non-essential
amino acids, 0.03% L-glutamine and 50 jg ml-' gentamycin.
Plasmids
In this experiment, the AAV DNA was introduced into cells
in a recombinant plasmid form instead of virus. The
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advantages of using a cloned AAV are that the pSV2Neo
vector contains a neo gene by which the recombinant
plasmid-harbouring cells can be selected after transfection;
the recombinant plasmids are much easier to purify than the
viruses, and the plasmid is less of a biohazard than the
infectious viruses. The wild-type AAV-2 genome (4.7 kb) was
obtained from the pAVI plasmid (Laughlin et al., 1983) by
BgllI and PvuII digestion. The left distal 1.0 kb of the rep
gene was deleted by BamHI digestion to give a 3.7 kb
fragment containing a truncated rep gene. Alternatively, part
of the cap gene (1.1 kb) was deleted by ApaI digestion to
yield a 3.6 kb AAV fragment. This fragment was further
digested by MscI to remove the 125 base ITRs at both ends
generating a 3.35 kb fragment. The wild-type or mutated
AAV DNA was then cloned into pSV2Neo vector at the
BanHI site. The recombinant plasmids carrying wild-type
AAV, truncated rep gene, truncated cap gene, or both cap
and ITRs deleted insertions are designated pAVNeo, pAVR,
pAAV and pAITR respectively (Figure 1). The plasmids were
purified by alkaline lysis followed by caesium chloride
ultracentrifugation (Sambrook et al., 1989).
Transfection and selection
The pSV2Neo vector, or one of the recombinant plasmids
described above, was transfected into cells by the lipofection
method (BRL). Briefly, cells at a density of about 80%
confluence in a 60 mm dish were plated one day before
transfection. DNA (5 pg) and lipofectin (20 pg), each in
100 p1 of water, were mixed at room temperature for 15 min.
The lipofectin-DNA mixture was added dropwise to the
cells in Opti-medium (Gibco) and incubated at 37°C for 8 h.
One day later, the transfected cells in a 60 mm dish were split
into five 100 mm dishes. After 24 h, 1.5 mg ml-' geneticin
sulphate (G418; Gibco) at a concentration sufficient for 90%
inhibition of cell growth (ID90) within 3 days was applied to
select for the plasmid-harbouring cells. Ten to 14 days after
selection, the survival cells formed at least 50 colonies per
100 mm dish; these colonies were then pooled as a mixture
culture and used in this experiment. The ID50 (0.8 mg ml-')
of G418 was subsequently employed to maintain the cells.
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Fugre 1 Structures of AAV genome and plasmids containing
wild-type and mutated AAV genome. (a) AAV genome map. The
bottom line shows the 4.71kb AAV genome; the black dots denote
three transcription promoters (p5, p19 and p4O). The solid boxes
at both ends of the top line indicate inverted terminal repeats
(ITRs), the origins of replication; the open rectangles show the
open reading frames of the replication (rep) gene and the capsid
(cap) gene. (b) The top line represents the wild-type AAV DNA.
The second line represents the rep gene truncated at base no. 1045
by BamHI (B). The gap in the third line represents the cap gene
deleted by ApaI (A). The deletion was made from nucleotide 2947
to 4044. The open boxes on the bottom line represent deletion of
both ITRs at nucleotide 125 and 4550 by MscI (M). The
pSV2Neo DNA is not shown in this figure.
designated SVNeo-HeLa and AVNeo-HeLa respectively.
Similarly, SiHa cells transfected with one of the aforemen-
tioned plasmids containing wild-type or mutated AAV are
referred to as SVNeo-SiHa, AVNeo-SiHa, AVR-SiHa, AAV-
SiHa or AITR-SiHa.
Determination of AA V copy number in cells
The AAV copy number in cells was determined by slot-blot
analysis. Various amounts of the 4.7 kb AAV DNA were
loaded onto nylon membrane and hybridised with a 3p_
labelled AAV probe. The resultant radioactivity was plotted
against AAV copy number to generate a standard curve. The
radioactivity obtained from the genomic DNA was inter-
cepted into the standard curve to yield the AAV copy
number. The copy number per cell was calculated by
normalising the genomic DNA amounts into cell numbers.
Detection of AAV DNA replication
Monolayer cells in a 100 mm dish were infected with
adenovirus type 5 (Ad 5) (2.3 x 1010 virus particles). Two
days after infection, cells were lysed with 2.5 ml of Hirt's
solution [10 mm Tris-HCl, pH 7.4, 1 mM EDTA, 0.1 M
sodium chloride and 1% sodium dodecyl sulphate (SDS)]
and the lysate was passed through a glass wool column to
remove the cellular DNA. The flow-through containing the
viral DNA was treated with 200 pg ml-' proteinase K,
extracted with phenol-chloroform, and analysed in a 1%
agarose gel. The DNA was then transferred to nitrocellulose
paper and hybridised with a 32P-labelled AAV probe.
Assay of turnorigenicity in vivo
Tumorigenicity of cervical carcinoma cells was assayed in 4-
to 6-week-old female athymic nude mice. Cells suspended in
0.1 ml of phosphate-buffered saline (PBS) were injected
subcutaneously near the shoulders of the mice. The size of
tumour in situ was measured in three dimensions at various
times after injection. Animals were sacrificed when the
tumour grew to more than 1 cm im diameter or 2 months
later, whichever came first.
Results
Detection ofintegrated AAV DNA in HeLa and SiHa cells
The AAV genome usually integrates into the host chromo-
some during latent infection; it can be 'rescued' and
undergoes replication upon superinfection with a helper
virus (Samulski et al., 1982). To examine whether the
recombinant AAV plasmids were integrated into cell
chromosomes, the AAV-transfected cells were infected with
Ad 5 helper viruses. Figure 2 shows that the wild-type
replicative form (RF) and its dimer form were observed in
both AVNeo-HeLa and AVNeo-SiHa cells (Figure 2a and b,
lane 3). The replication products were absent from both
parental and SVNeo-HeLa (Figure 2a, lanes 1 and 2) and
from both parental and SVNeo-SiHa cells (Figure 2b, lanes 1
and 2). These results suggest that some of the transfected
AAV DNA sequences remain integral so that they can be
rescued by helper virus in HeLa and SiHa cells. On the other
hand, no AAV DNA was observed from AVNeo-HeLa or
AVNeo-SiHa cells without Ad 5 infection (data not shown).
These findings imply that most of the AAV DNA may
integrate into host cell chromosomes, whereas the AAV DNA
remaining in an episomal form may be rare. The issue of
whether the AAV DNA integrates into cell chromosomes at a
specific site as described by others (Kotin et al., 1992; Walz
and Schlehofer, 1992) remains unresolved.
The existence ofmutant AAV DNA in SiHa cells was also
examined by Ad 5 rescue assay. Owing to the deletion of a
1.1 kb fragment of the cap gene, the RF size in AAV-SiHa
was 3.6 kb whereas no single-stranded (s.s.) DNA could beAdeno-associated vrus spess cervical carcinoma
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found (Figure 2b. lane 5). The data agree with those of other
researchers (Hermonat et al.. 1984) who reported that
deletion in the cap gene exerts no effect on AAV replication
but reduces the accumulation of s.s. DNA. It has been
reported that the rep gene and the ITRs are required for the
rescue of AAV DNA and AAV DNA replication (Senapathy
et al.. 1984: Samulski et al.. 1983). These conclusions are
further extended by our studies. The replication products
were absent in both AVR-SiHa cells in which the rep gene
was truncated (Figure 2b. lane 4) and AITR-SiHa cells in
which both ITRs were deleted (Figure 2b. lane 6). The
existence of these two mutated AAV genomes in cells was
proven by slot blotting as shown in Figure 3.
Effect ofAA on the in viio tumorigenicitv ofHeLa and SiHa
cells
To determine whether AAV transfection affects the in viio
tumorigenicitx of human cervical carcinoma cells. HeLa and
SiHa cells transfected with or without AAV plasmids were
injected into nude mice and the sizes of the resulting tumours
were measured. The data reveal that the mean sizes of
tumours arising from parental. SVNeo-. and AVNeo-HeLa
cells were 587.6. 435.2 and 442.8 mm' respectivelv. indicating
that the tumorigenicity of HeLa cells was not affected by
AAV transfection.
Figure 4 showxs that the tumours derived from SVNeo-
SiHa cells appeared later than those derived from SiHa cells.
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vet bx dav 40 the tumour sizes from both cell lines were
similar. The sizes of tumours of the parental and SVNeo-
SiHa cells were 62.0 and 54.0 mm respectively. The relative
sizes of tumours from AVNeo-SiHa (8.0 mm") and AAV-
SiHa (4.5 mmr) cells decreased noticeablv to 13°o and 70o
respectively. whereas the sizes of tumours arising from AVR-
SiHa (115.5 mm') and AITR-SiHa (92.8 mm") were much
larger as compared with those of the tumours from parental
SiHa cells. These results suggest that the tumorngenicitv of
SiHa cells was suppressed by the presence ofwild-type AAV.
Mutation of the rep gene or ITR abolishes the oncosuppres-
si7e activitx of AAV. whereas deletion of the cap gene exerts
no effect.
Effect of AA V on the growtth rate and anchorage-independent
activity of SiHa cells
The effects of AAV on the in vitro biological properties of
cells were examined by measuring cell proliferation actixvitv
and the abilitv to form colonies in soft agar. Figure 5 show-s
that HeLa and SiHa cells had similar growth rates betx-een
the parental and transfected cells (Figure 5a and b). Table I
reveals that relativ-e colonx formation efficiency was decreased
in AVNeo-HeLa cells as compared with that of parental
HeLa cells. yet the degree of reduction wAas similar to that of
SVNeo-HeLa. In SiHa cells. the efficiencv of AVNeo-SiHa
cells was about half that of parental SiHa cells. The efficiency
of SVNeo-SiHa cells. hoxuever. was only about 6600 that of
parental cells. indicating that the changes in efficiencv due to
the presence of AAV were slight.
The reasons accounting for the mild changes may be that
oncogenesis is believed to be a multiple-step process: normal
cells escape from cell senescence. lose tumour-suppressor
genes. activate oncogenes and then become tumorigenic. In
the present model system. AAV probably reverses the
transformation properties of SiHa cells from tumorigenic to
non-tumorigenic With no further conversion.
Discussion
This report describes the differential responsixveness of txo
human cervical carcinoma cell lines to AAV DNA
Figure 2 Southern blot anal -sis of the .kAA DNNA rescued b-
adenovirus type 5 (Ad5) infection. Monolaver cells w-ere infected
with Ad 5 until the cytopathic effect w-as obserxed. The small
molecular weight DNA w-as extracted and analysed on an agarose
zel as described in Materials and methods. (a) Lane 1. HeLa: lane
2 SVNeo-HeLa: and lane 3. AVNeo-HeLa. (b) Lane 1. SiHa:
lane 2. SVNeo-SiHa: lane 3. AVNeo-SiHa: lane 4. AVR-SiHa:
lane 5. AAV-SiHa: and lane 6. AITR-SiHa. The dimer. replicatixe
form (RF) and single-stranded DNA are denoted by *. 0 and 0
symbols respectively.
SiHa
SVNeo-SiHa
AVR-SiHa
AITR-SiHa
Figure 3 Slot-blot analysis of AA\ DNA in SiHa cells. Cellular
DNA was purified with proteinase treatment followxed bv
phenol-chloroform extraction. Cellular DNTA was cleaved with
XbaI to reduce the size of DNA molecules. The DNA (1. 10 and
50gig) was applied to nvlon membranes by using a slot-blot
apparatus (Schleicher and Schuell) and hvbn'dised with a '2P-
labelled AAV probe.
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Figure 4 In vivo tumorigenicity analysis of parental. pSV2Neo-.
wild-type AAV- and mutant AAV-transfected SiHa cells. Cells
(1.5 x 106) in 0.1 ml PBS were injected into the shoulders of each
mouse. The figure shows a comparison of the tumour size at
various times after injection. Each point represents the mean
*-alue of the tumour sizes measured at fixve injection sites.
< _ 1.
l
IAdeno-associated virus suppressor cervical c
P-F Su and F Y-H Wu
1536
-0--C- HeLa
-SVNeo-
HeLa
-0-C- AVNeo-
HeLa
.0
E U 1 z X 4 b
C:
b Q0 _ _-r _ - _ (.,2.50EU+U0
2.OOE + 06
1.50E + 06
1.OOE + 06
5.OOE + 05
O.OOE + OC
0 1 2 3 4 5
Time (days)
Figure 5 Companrson of the growth rate of parental. pSV2Neo-
and pAVNeo-transfected HeLa (a) or SiHa (b) cells. Cells
(1.0 x 105 for HeLa or 2.0 x 105 for SiHa) were plated into a
35 mm dish and were cultured in medium with 2"Io fetal calf
serum. Cell number was counted daily for 5 days.
transfection. The results of in vivo nude mice assays suggest
that the tumorigenic phenotype of SiHa cells but not that of
HeLa cells is significantly inhibited in the presence of AAV.
although the existence of AAV DNA in both cell lines was
proven by Ad 5 rescue assay.
The mechanism of AAV's differential suppression is still
not understood. However, the copy ratio of AAV to HPV in
cells may play an important role. Since the AAV DNA
molecules were found to be approximately 1 -3 per
transfected cells. the ratio of AAV to HPV in HeLa and
SiHa is then deduced to be 1-3 50 and 1-3 1-2
respectivelyx. HPV is one of the possible inducers of cervical
carcinoma and its E6 and E7 gene products are known to be
associated with HPV's transformation activity. The inhibitory
activity of AAV has been proposed to be exerted via the
suppression activity of rep gene products on viral promoters
containing Spl sequences (Hermonat. 1991). The Spl element
has been found in the E6 E7 promoter of HPV-16 (Gloss and
Table I Anchorage-independent actiVity of the parental.pSV2Neo.
and pAVNeo-transfected HeLa or SiHa ceilsa
Relative efficienci
Cell No. ofcolonies" %
HeLa 404_40.6 100.0
SVNeo-HeLa 359+ 33.4 88.9
AVNeo-HeLa 317-- 13.9 78.5
SiHa 703 +50.2 100.0
SVNeo-SiHa 425-+ 18.5 60.5
AVNeo-SiHa 337+4.8 47.9
aThe procedures used are those of Adams (1980) with some
modifications. In a 60mm dish. 1.5 ml of the cell suspension
(4.5 x 103 for HeLa or 3 x 103 for SiHa) in 0.3%o agar was placed on
a 7ml. 0.500 agar medium layer. After plating. HeLa cells were
incubated for 8 days and SiHa cells for 10 days. The colonies were
stained with 1 ml of 0.05% p-indonitrotetrazolium violet dve. bMean
value +s.e. The data presented are one of three independent assays.
Bernard. 1990) and recent reports show that the promoters of
HPV-16 (Hermonat, 1994) and HPV-18 (Horer. 1995) are
repressed by AAV. Our immunoprecipitation analysis also
showed that AAV transfection reduced the amount of E7
protein by 33% in SiHa cells (P-F Su and F Y-H Wu.
manuscript in preparation). We therefore propose that a low
copy number of the AAV genome is unable to overcome a
large amount of HPV gene products in HeLa cells. On the
contrary. AAV may probably compromise the low amount of
HPV gene products in SiHa cells, thus exerting an
oncosuppressive effect. A recent study (Walz and Schleho-
fer. 1992) has shown that the growth rate of tumours induced
by HeLa cells is reduced by AAV infection. Since DNA
transduction efficiency of virus infection is higher than that of
DNA transfection, it may be that more AAV DNA molecules
were introduced into HeLa cells during the experiment. The
tumorigenicity of HeLa cells is therefore partially suppressed.
Our preliminary results (P-F Su and F Y-H Wu. manuscript
in preparation) have shown that increasing AAV copy
number by cloning the AAV DNA into an episomal form
Epstein-Barr virus-based vector can reduce the tumorigeni-
city of HeLa cells. It supports our 'copy number hypothesis'
that the more AAV DNA being introduced or the higher
AAV gene expression can exert. the higher AAV's inhibitory
activity.
Several other factors may also contribute to the observed
differential inhibition by AAV in our study. The integration
site of a cloned AAV DNA and the correlation between the
integration site and the oncosuppressive activity is still
elusive. The resolution of whether the differential suppres-
sion is caused by different integration awaits further studies.
The difference of HPV type between cells, the differentiation
state of cells and the expression activity of the rep gene in
SiHa and HeLa cells may also affect the suppressive activity
of AAV in cells.
To define the control motifs. various deletion mutants of
the AAV genome were constructed as shown in Figure 1. The
in vivo tumorigenicity assay revealed that very small tumours
formed in nude mice that were injected with SiHa cells
transfected either with wild-type or with cap gene-deleted
AAV DNA. In contrast. when the rep gene was truncated by
deleting the left-end 1 kb or when both ITRs of AAV
genome were removed. the oncosuppressive activity of AAV
was abolished (Figure 5). These data clearly demonstrate that
an intact rep gene and ITRs. but not an intact cap gene. are
required for the oncosuppressive effect of AAV. The
requirement of the rep gene or its products for oncosuppres-
sive activity agrees with previous studies (Hermonat. 1989;
Yang et al.. 1992) that have demonstrated that the rep gene is
directly related to AAV's suppression of cellular transforma-
tion. ITRs have been reported to have enhancer activity
(Beaton et al.. 1989): deletion of ITR may reduce the
expression of the rep gene leading to the loss of AAV's
AAdn-o mosoWrd vins m a c carcno-a
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suppressive activity. On the other hand, ITR is needed for
AAV DNA integration. Deletion of one or both ITRs may
lead to an improper integration and deactivate the inhibitory
function of AAV. Our results further indicate that mutation
within the rep gene or ITR not only abolishes the inhibitory
effect of AAV but also enhances the tumorigenicity of cancer
cells. These observations point out the importance of the
integrity of AAV sequence in its therapeutic applications.
The differential inhibitory effect of AAV on the
tumorigenicity of HeLa and SiHa cell observed in this study
has shed light on the interaction between AAV and HPV.
This system can serve as a model to further elucidate the
oncosuppressive mechanism of AAV, knowledge of which is
a prerequisite for understanding the process ofcarcinogenesis
and using AAV as an agent for gene therapy.
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